Välj din region

Välj den region som bäst passar din plats eller dina preferenser.

International

Välj ditt webbplatsspråk

Denna inställning styr språket för användargränssnittet, inklusive knappar, menyer och all text på webbplatsen. Välj ditt föredragna språk för bästa surfupplevelse.

Välj språk för jobbannonser

Välj de språk för jobbannonser du vill se. Denna inställning avgör vilka jobbannonser som visas för dig.

Pieris Pharmaceuticals GmbH

Freising, Tyskland

Prenumerera på nya jobb

Besök webbplats

Om arbetsgivaren

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin^® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.

Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.

Pieris has a diverse pipeline of Anticalin Therapeutics for a number of different indications and has active, multi-program R&D collaborations with Roche, Daiichi Sankyo, the Sanofi Group, Zydus Cadila and Stelis Biopharma.

Pieris, founded in 2001, was funded by premier biotechnology-focused venture capital firms including OrbiMed Advisors as its lead investor as well as Forbion Capital, Gilde Healthcare Partners, Novo Nordisk Ventures, Global Life Science Ventures, BayTech Venture Capital, Bio-M, TCB, KfW and BayernKapital.

Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).